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Introduction: Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) is an 
autosomal recessive lysosomal storage disorder, characterized primarily by skeletal dysplasia and 
joint contracture. It is caused by a deficiency of N-acetylgalactosamine-4-sulfatase (arylsulfatase B), 
for which a recombinant formulation (galsulfase) is available as replacement therapy.
Objective: To evaluate the effectiveness and safety of galsulfase compared to placebo or no 
interventions, for treating MPS VI. We also considered studies evaluating different doses of 
galsulfase.
Methods: A systematic review of the literature was conducted. A computerized electronic 
search in MEDLINE, EMBASE, CENTRAL, SciELO, and LILACS was carried on to identify 
any randomized trials that met our inclusion criteria.
Results: Two studies were included in the review. Because the number of studies was small, our 
analysis probably did not find any statistically significant difference. Long-term follow-up will be 
required to ascertain full clinical benefit, on both event-free survival and quality of life measures.
Conclusions: There is some evidence to support the use of galsulfase in the treatment of 
MPS VI; however due to the very low quantity of included studies we could not analyze it in an 
appropriate way. This review highlights the need for continued research into the use of enzyme 
replacement therapy for MPS VI.
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systematic review
Introduction
The mucopolysaccharidoses represent a group of lysosomal disorders characterized 
by the progressive accumulation of glycosaminoglycans (GAG) in multiple cell types; 
which occurs as a consequence of distinct deficiencies in the enzyme responsible 
for GAG degradation. Each subtype is assigned a number, based on its chronologic 
description, and an eponym, in recognition of the clinician(s) involved in its initial 
delineation. As a group, the incidence of MPS disorders has been estimated at 1 in 
25,000. Enzyme replacement therapy is available for MPS types I, II, and VI.
Mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy syndrome, 
is caused by the deficiency of N-acetylgalactosamine-4-sulfatase (arylsulfatase B, 
ASB) and the resultant tissue storage of dermatan sulfate. Clinical manifestations 
include distinctive facial features, skeletal dysplasia leading to short stature, joint 
contractures, and cardio-pulmonary involvement. Patients have reduced exercise 
capacity and endurance, and limitations in joint range of motion. It is a relatively rare 
disorder, with an estimated incidence of 1 in 248,000 to 1 in 300,000.Biologics: Targets & Therapy 2009:3 460
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In clinical trials, a recombinant formulation (galsulfase, 
rhASB; Naglazyme®) has been shown to be safe and effective 
in the treatment of MPS VI, when compared to placebo or 
no interventions.
After the performance of a rigorous search strategy in the 
electronic databases it was not verified a systematic review 
about this topic. Therefore, we proposed to summarize and 
organize studies about galsulfase for MPS VI through a 
systematic review, because of its potential internal validity 
and to provide assistance to physicians and consumers about 
the best evidence available in the literature.
Method
Literature search
There was no language restriction. Trials were obtained 
from the following sources: Cochrane Central Register of 
Controlled Trials (CENTRAL, The Cochrane Library, issue 
1, 2009), Publisher’s MEDLINE (Pubmed; 1966–2009), 
Excerpta Medica database (EMBASE; 1980–2009), 
Scientific Electronic Library Online (SciELO; 2009) and, 
Literatura Latino-Americana e do Caribe em Ciências 
da Saúde (LILACS; 1982–2009) to identify randomized 
and quasi-randomized controlled clinical trials that met 
our inclusion criteria. The date of the last search was 
March 2009.
The following databases of ongoing trials were also 
searched: National Institutes of Health database of Ongoing 
Clinical trials (www.clinicaltrials.gov) and Current 
Controlled Trials (www.controlled-trials.com).
The databases were searched using a comprehensive 
search strategy for mucopolysaccharidosis VI and galsul-
fase including an exhaustive list of synonyms. The search 
strategy was adapted for each database in order to achieve 
more sensitivity. References in the relevant studies identi-
fied were also scrutinized for additional citations. The 
summary of the bibliographic search strategies for type of 
clinical situation and intervention of interest are shown in 
Table 1.
Data collection
The authors independently screened the trials identified by 
the literature search, extracted the data, assessed trial quality 
and analyzed the results. A standard form was initially used 
to extract the following information: study characteristics 
(type of design and randomization methods), participants, 
interventions, and outcomes (Appendix 1).
Study selection
We planned to include randomized and quasi-randomized 
controlled trials that specifically stated that the conditions 
under investigation were galsulfase and which involved adults 
and/or children diagnosed with MPS VI based on biochemical 
confirmation of ASB deficiency. Also, we considered studies 
evaluating different doses of galsulfase.
The following efficacy outcome measurements were 
assessed when available, in reports of studies that meet the 
inclusion criteria described above:
1.  Endurance variables, such as distance walked in a 
12-minute walk test (12MWT) and number of stairs 
climbed in a 3-minute stair climb test (3MSC);
2.  Joint mobility (shoulder, elbow, and knee), grip and pinch 
strength;
3.  Joint function;
4.  Level of urinary GAG excretion; and
5.  Laboratory abnormalities.
Safety was evaluated by compliance, adverse events, 
drug-related serious adverse events, and adherence to the 
treatment protocol.
Methodological quality assessment
The methodological quality of the trials included in this review 
was judged using the Cochrane instrument approach recom-
mended by the Cochrane Handbook.1 We assessed the following 
6 separate criteria: adequate sequence generation; allocation 
concealment; blinding; incomplete outcome data addressed 
(withdrawal and/or drop outs), and other sources of bias.
Data analysis
We considered clinical trials available in the literature to plot in 
a meta-analysis with relative risk (RR) for dichotomous data, 
and weighted mean difference for continuous data; with their 
95% confidence interval (CI). Intention-to-treat analysis was 
carried out for dichotomous data when possible. Participants 
who dropped out were assumed to be non-respondents.
Inconsistency among the pooled estimates was quantified 
using the I2. This illustrates the percentage of the variability 
in effect estimates resulting from heterogeneity rather than 
sampling error.2,3
Table 1 Summary of the bibliographic search strategies for type 
of clinical situation and intervention of interest
Search history
((Mucopolysaccharidosis vi) Or (Mucopolysaccharidosis vis) Or
(Mucopolysaccharidosis vis) Or (Mucopolysaccharidosis 6) Or
(Polydystrophic Dwarfism) OR (Maroteaux-Lamy Syndrome)
Or (Maroteaux Lamy Syndrome)) AND (Galsulfase Or Naglazyme Or
(N-Acetylgalactosamine-4-Sulfatase) Or rhASB))Biologics: Targets & Therapy 2009:3 461
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Results
Description of studies
Study selection
Approximately 235 titles were identified through the search 
strategy of the electronic databases (see Figure 1). Following 
assessment of 14 full text articles only nine publications 
were considered for inclusion in this review. Six studies were 
subsequently excluded,4–9 representing case series, cohort 
studies, and an open-label extension study. Two studies 
(3 publications) which met the minimal methodological 
requirements were included in the review.10–12
included studies
Two studies (3 publications) were included in this review10–12 
with a total of 46 participants.
Design of the studies
Summary details are given in Table 3.
The Harmatz 200610 study was a multicenter phase III 
randomized, double-blind, placebo-controlled trial wherein 
subjects were recruited from 6 clinical sites. The Harmatz 
2004/Harmatz 200511,12 study involved subjects enrolled in the 
single-site phase I/II randomized double-blind, 2-dose trial; 
235 
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Figure 1 Flow chart of the systematic review.Biologics: Targets & Therapy 2009:3 462
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data on the pharmacokinetics of galsulfase were presented 
in the latter report.
Participants and duration of trials
In the Harmatz 200610 study a total of 39 subjects participated 
in the study. Gender distribution: rhASB group, 12 females 
and 7 males; placebo group, 14 females and 6 males. Mean 
age: rhASB group, 13.7 years and; placebo group, 10.7 years. 
The follow-up period was 24 weeks; all of the patients that 
completed the 24 weeks study were enrolled in the open-label 
extension. The inclusion criteria were as follows: 7 years 
of age and have either a biochemical or molecular analysis 
result consistent with the diagnosis of MPS VI. At screening, 
patients should be able to walk unaided at least 5 meters (m) 
and no more than 270 m in the first 6 minutes, or no more 
than 400 m in 12 minutes, in a 12MWT. Patients who had 
clinically significant spinal cord compression, or a medical 
condition or other circumstance that could interfere with 
study compliance were excluded.
In Harmatz 2004/Harmatz 200511,12 study a total of 
7 subjects participated in the study. There were 3 females 
and 4 males, aged from 7 to 16 years. The follow-up period 
was 48 weeks (after the 24-week safety and efficacy evalua-
tions, the study blind was removed, but all patients remained 
on their assigned dose until after the 48-week evaluation). 
The diagnosis of MPS VI was confirmed, based on decreased 
leukocyte ASB enzyme activity.
Types of intervention
In the Harmatz 200610 study, participants were randomized to 
receive weekly intravenous infusions of either rhASB 1.0 mg/kg 
or placebo solution during this first 24 weeks. In Harmatz 
2004/Harmatz 200511,12 study, patients were randomized to 
weekly infusions of either high (1.0 mg/kg; n = 3) or low 
(0.2 mg/kg; n = 4) doses of rhASB.
Types of outcome measures
The following were the primary and secondary efficacy 
endpoints of the Harmatz 200610 study: distance walked 
in a 12MWT, number of stairs climbed in a 3MSC, and 
the level of urinary GAG excretion. Others endpoints 
included: (i) assessments of joint pain, joint stiffness, and 
physical energy level; (ii) assessment of joint range of 
motion; (iii) assessment of hand dexterity as evidenced by 
the number of coins picked up in 1 minute; (iv) clinical 
parameters such as respiratory and cardiac function, and 
ophthalmologic tests. The safety outcomes were adverse 
events, serial assessment of immunologic parameters 
and electrocardiography, and monitoring of changes in 
laboratory parameters (chemistry, hematology, urinalysis, 
thyroid function).
The Harmatz 2004/Harmatz 200511,12 study evaluated 
mobility and physical function, including 6MWT, joint 
range of motion (shoulders, elbows, and knees), spirometry, 
and assessment of functional status, toxicity, total GAG, 
pharmacokinetic parameters, and ophthalmologic and 
electrocardiogram evaluations. Other measurements included 
liver volume, lumbar vertebral trabecular bone density, 
polysomnography, and adverse events.
Excluded studies
Six studies are described in the Table 2,4–9 which were 
excluded as these were non-randomized or quasi-randomized 
controlled trials.
Ongoing trials
We identified one trial registered in the electronic databases 
of ongoing trials which is in the recruitment stage: a phase IV 
trial with the aim of assessing the safety and efficacy of 2 dose 
levels of galsulfase in infants (1 year) who have MPS VI.
Awaiting assessment
No study is awaiting assessment.
Methodological quality of included studies
Allocation (sequence generation and allocation 
concealment)
The Harmatz 200610 and Harmatz 2004/Harmatz 200511,12 
studies did not report the generation of allocation or the allo-
cation concealment making this study classified as ‘unclear’.
Blinding
The Harmatz 200610 study described the blinded assessment 
of outcomes as follows: both the investigator and staff did not 
participate in the efficacy assessments and were not informed 
of the original treatment assignments. The study ‘meets’ the 
criteria for blinding.
The Harmatz 2004/Harmatz 200511,12 study did not 
describe whether investigators and/or patients were blinded 
to the treatment allocation as well as to the assessment of 
outcomes, therefore, the study was classified as ‘unclear’.
Description of drop-outs/withdrawals
The Harmatz 200610 study reported withdrawals in more 
than 20% (11 patients were randomized and did not fulfill 
inclusion criteria); therefore, the assessment of attrition bias 
was recorded as ‘not met’. The study used an intention-to-treat Biologics: Targets & Therapy 2009:3 463
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analysis of efficacy variables (eg, included all patients who 
were randomized); whereas safety analysis included patients 
who received at least one dose of the study drug.
Although the Harmatz 2004/Harmatz 200511,12 study 
reported the occurrence of withdrawal or drop-outs 
(ie, 6 patients completed 24 weeks of treatment and 5 patients 
completed 48 weeks), the study was classified as ‘not met’. 
The authors did not use an intention-to-treat analysis.
Effect of interventions
It was not possible to combine the included studies10–12 in 
a meta-analysis because the interventions compared were 
different: the Harmatz 200610 study compared rhASB 1.0 mg/kg 
versus placebo, while the Harmatz 2004/Harmatz 200511,12 
study evaluated different doses of rhASB (1.0 mg/kg versus 
0.2 mg/kg). Therefore, we present only a representation of 
the meta-analysis to facilitate the interpretation of the results 
found in both studies.
Discussion
We have found some evidence to support the use of 
galsulfase in the treatment of MPS VI. Although we aimed 
to identify the best clinical evidence available to answer 
our question, and performed an extensive search and care-
ful quality assessment, only few conclusions can be drawn 
from the trials we evaluated. This review has been limited 
by the low quantity of the trials available for inclusion. The 
methodological descriptions reported inadequate methods of 
randomization and allocation concealment, and there were 
limitations to blinding. Furthermore, both included trials 
did not address the same control groups, and for this reason 
the pooling of data was not possible. In addition, the small 
number of trials meant that our intended sensitivity analyses 
were not possible. Furthermore, although we did not perform 
any funnel plot to address the possibility of publication bias 
due to the very small number of clinical trials included in 
this review, the possibility of residual confounding due to 
unmeasured studies cannot be ruled out.
Enzyme therapy for MPS VI using galsulfase has been 
shown to result in clinical improvements in endurance 
(as measured by the 12MWT and 3MSC test) along with 
a reduction in urinary GAG levels, using the approved 
prescribed dose of 1.0 mg/kg of rhASB, administered weekly. 
In the phase III trials, patients receiving rhASB walked 
on average 92 m more in the 12MWT and 5.7 stairs per 
minute more in the 3MSC than patients receiving placebo. 
Continued improvement was observed during the extension 
study. Urinary GAG declined by –227 ± 18 µg/mg more with 
rhASB than placebo. Proof of therapeutic principle is based 
on the lowered level of urinary GAG in all treated patients, 
which was sustained with on-going treatment. Long term 
follow-up will be required to ascertain full clinical benefit, 
on both survival and quality of life measures.
The observation in the phase III study essentially 
confirmed the results noted in the phase I/II study of rhASB, 
using 2 different enzyme doses (0.2 and 1 mg/kg). In the 
latter study, reduction in total GAGs was shown to be dose 
dependent, and became the basis for examining safety and 
efficacy at the 1 mg/kg dose in subsequent trials.11 Additional 
observations in case series study8 were an improvement in 
Table 2 Characteristics of excluded studies
Study ID Reason for exclusion
Scarpa 20094 Case series
Bagewadi 20085 Case series
Cardoso-Santos 20086 Cohort study
Harmatz 20087 Open-label extension study
Harmatz 20058 Case series
Azevedo 20049 Cohort study
Table 3 Summary details of included studies
Study ID Study Design Number of patients 
(enrolled/completed)
Gender and age rhASB doses Duration of 
therapy (weeks)
Harmatz 200610 Phase iii randomized, 
double-blind, placebo-
controlled trial
39/38 rhASB group: 12 females 
and 7 males. Placebo group: 
14 females and 6 males
rhASB group: 13.7 years 
Placebo group: 10.7 years
weekly intravenous 
infusions of either 
rhASB 1.0 mg/kg 
or placebo
24
Harmatz 
2004/Harmatz 
200511,12
Phase i/ii randomized 
double-blind, two-dose 
trial
7/6 3 females and 4 males, aged 
from 7 to 16 years
weekly infusions of 
either high (1.0 mg/kg) 
or low (0.2 mg/kg) 
doses of rhASB
48Biologics: Targets & Therapy 2009:3 464
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each patient on average of 155 m (98%) in the 12MWT, 64 m 
(62%) at the 6-minute time point of the 12-minute walk, and 
a gain of 48 stairs (110%) in the 3MSC versus the baseline 
mean values, after 24 weeks of treatment. Dose-dependent 
responses were not seen in the functional parameters, possibly 
related to the small number of patients and large range of 
ages and disease severity within each group.8 Additional 
improvements after 48 weeks of treatment were noted, 
including mean values of 211 m (138%) in the 12MWT, 
75 m (80%) at the 6-minute time point of the 12MWT, and 
a 61-stair (147%) gain in the 3MSC versus the baseline 
mean values. Joint Pain and Stiffness Questionnaire scores 
improved by at least 50% by week 24 and were maintained 
at week 48, whereas there were only small improvements in 
active shoulder range of motion (10 degrees ) and in the time 
taken to stand, walk, and turn starting from a seated position 
(Expanded Timed Get-Up-and-Go test). Improvement in 
pulmonary function based on forced vital capacity and forced 
expiratory volume at 1 minute in the absence of growth was 
observed in 3 of 6 patients, and the observed gains occurred 
in the 24- to 48-week treatment interval. A mean decrease of 
76% in urinary excretion of GAGs was seen.
The reported increase in distance travelled, together with 
the increase in stairs climbed indicate that improvements 
in exercise capacity can be expected in MPS VI patients 
treated with galsulfase. The increase in performance during 
the extension phase of the trials indicates the results are 
sustained and durable. These gains are anticipated to improve 
Comparison: rhASB 1.0 mg/kg versus placebo 
(C1) Distance walked in a 12-minute walk test (12MWT)
Review: New advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase
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Figure 2 representation of meta-analysis from the Harmatz 200610 study that compared 1.0 mg/kg of rhASB versus placebo.   There was no statistically significant difference 
between both groups regarding the distance walked in a 12Mw test in any of the subcategories evaluated. Note that patients initially given placebo were given rhASB during 
subsequent infusions after the 24 week time point.
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Figure 3 representation of meta-analysis from the Harmatz 200610 study that compared 1.0 mg/kg of rhASB versus placebo. There was no statistically significant difference 
between both groups regarding the number of stairs climbed in a 3MSC test in any of the subcategories evaluated. Note that patients initially given placebo were given rhASB 
during subsequent infusions after the 24 week time point.Biologics: Targets & Therapy 2009:3 465
Galsulfase for MPS vi Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
affected patients’ ability to carry out activities of daily living, 
although this requires further longterm studies. In addition, 
the influence of therapy on patient survival remains to be 
established.
A follow up report7 in an open-label extension study has 
indicated that the improved endurance seen in patients after 
starting galsulfase was not sustained in some; which was 
attributed to advanced skeletal disease at study entry. The 
latter observation was considered to represent a high risk 
for disease progression in the hip and cervical spinal cord 
compression, which would have an adverse effect on affected 
patients’ performance. Intravenous administered rhASB 
does not penetrate the joint spaces or the central nervous 
system, and thus the therapy would not be expected to prevent 
progression of these complications.
Infusion related adverse reactions (IAR) were observed 
in over half the patients treated with rhASB. Anaphylactoid 
IARs were noted in 16% of patients; the term ‘anaphylactoid’ 
was used to refer to certain IARs, based on the nature of 
the event, its recurrence and response to treatment. These 
observations underscore the need to closely monitor patients 
given galsulfase; particularly as these patients may have 
pre-existing risks related to involvement of cardiopulmonary 
system as a consequence of ASB deficiency. The observed 
events were noted as consistent with immune reactions 
expected with infused recombinant proteins. The reactions 
were manageable, and responded to interruption of the 
infusion and adjustment of the rate of infusion as well as to 
the administration of supplemental antihistamines and anti-
inflammatory agents such as ibuprofen and corticosteroids.
The safety profile of the treatment in clinical trials was 
good, with most adverse events attributed to underlying 
disease manifestations rather than to treatment with rhASB. 
However, there was no statistical significance difference 
between both groups for any incidence and frequency of 
adverse events related to study drug during weeks 1 to 24 in 
the representation of meta-analysis (Figure 5).
Investigations into disease mechanism and the extent to 
which these processes are modified by enzyme therapy are 
necessary. It is possible new insights into pathogenesis may 
offer novel targets for therapeutic intervention, such as the 
use of substrate synthesis inhibition (with genistein).13
Reviewers’ conclusions
implications for practice
There is some evidence to support the use of galsulfase in the 
treatment of MPS VI, however due to the very low quantity of 
included studies we could not analyze it in an appropriate way. 
Therapeutic response may be influenced by disease stage, 
and early intervention may lead to better outcomes, although 
this subject requires further investigations. It is possible that 
certain aspect of the disease may be modified by a longer 
period of treatment, and additional data is anticipated from 
the observational database or registry program, which has 
been established as a post-regulatory approval commitment 
made by the drug manufacturer.
implications for research
This review highlights the need for continued research into the 
use of enzyme replacement therapy for MPS VI, to increase 
(C3) Adverse events and drug-related serious adverse events 
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Figure 4 representation of meta-analysis from the Harmatz 200610 study that compared 1.0 mg/kg of rhASB versus placebo. There was no statistically significant difference 
between both groups regarding the occurrence of adverse events during weeks 1–24 in the double blind period study.   There were no reported deaths in either patient groups. 
Note that patients initially given placebo were given rhASB during subsequent infusions after the 24 week time point.Biologics: Targets & Therapy 2009:3 466
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the number of studies, study participants and the period of 
observation so that outcome data can confirm the real benefit 
of the treatment. Future studies should also address the issue 
of compliance with treatment eg, the study must be designed 
to address efficacy and/or efficiency. Besides, future studies 
must also be adequately powered.
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Figure 5 representation of meta-analysis from the Harmatz 200610 study that compared 1.0 mg/kg of rhASB versus placebo. There was no statistically significant difference 
between both groups regarding any incidence and frequency of adverse events related to study drug during weeks 1 to 24. Note that patients initially given placebo were given 
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Comparison: 1.0 mg/kg of rhASB versus 0.2 mg/kg of rhASB
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Comparison:
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Figure 6 representation of meta-analysis from the Harmatz 2004/2005 study that compared 1.0 mg/kg of rhASB versus 0.2 mg/kg of rhASB. There was no statistically 
significant difference between both groups regarding the percentage reduction in urinary GAG at week 24. Note that patients initially given placebo were given rhASB during 
subsequent infusions after the 24-week time point.Biologics: Targets & Therapy 2009:3
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